228 related articles for article (PubMed ID: 30339275)
21. Diversity of oncopharmacogenetic profile within Spanish population.
Ferrer Bolufer I; Galiana Vallés X; Izquierdo Álvarez S; Serrano Mira A; Guzmán Luján C; Safont Aguilera MJ; González Tarancón R; Bolaños Naranjo M; Carrasco Salas P; Santamaría González M; Rodríguez-López R
Pharmacogenet Genomics; 2024 Jul; 34(5):166-169. PubMed ID: 38488402
[TBL] [Abstract][Full Text] [Related]
22. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
[TBL] [Abstract][Full Text] [Related]
23.
Deligonul A; Aksoy S; Tezcan G; Tunca B; Kanat O; Cubukcu E; Yilmazlar T; Ozturk E; Egeli U; Cecener G; Alemdar A; Evrensel T
Genet Test Mol Biomarkers; 2021 Apr; 25(4):276-283. PubMed ID: 33877893
[No Abstract] [Full Text] [Related]
24. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
25. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis.
Sharma BB; Rai K; Blunt H; Zhao W; Tosteson TD; Brooks GA
Oncologist; 2021 Dec; 26(12):1008-1016. PubMed ID: 34506675
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
Cortejoso L; García-González X; García MI; García-Alfonso P; Sanjurjo M; López-Fernández LA
Pharmacogenomics; 2016 Jun; 17(9):979-84. PubMed ID: 27248859
[TBL] [Abstract][Full Text] [Related]
27. Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction.
Medwid S; Wigle TJ; Ross C; Kim RB
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686089
[TBL] [Abstract][Full Text] [Related]
28. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms.
Deng X; Hou J; Deng Q; Zhong Z
World J Surg Oncol; 2020 Dec; 18(1):321. PubMed ID: 33280607
[TBL] [Abstract][Full Text] [Related]
30. Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
Miarons M; Manzaneque Gordón A; Riera P; Gutiérrez Nicolás F;
Oncologist; 2023 May; 28(5):e304-e308. PubMed ID: 37014829
[TBL] [Abstract][Full Text] [Related]
31. Survival of Patients With Cancer With
Knikman JE; Wilting TA; Lopez-Yurda M; Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Nieboer P; Droogendijk HJ; Creemers GJ; Mandigers CMPW; Imholz ALT; Mathijssen RHJ; Portielje JEA; Valkenburg-van Iersel L; Vulink A; van der Poel MHW; Baars A; Swen JJ; Gelderblom H; Schellens JHM; Beijnen JH; Guchelaar HJ; Cats A
J Clin Oncol; 2023 Dec; 41(35):5411-5421. PubMed ID: 37639651
[TBL] [Abstract][Full Text] [Related]
32. Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients.
Pinheiro M; Peixoto A; Rocha P; Santos C; Escudeiro C; Veiga I; Porto M; Guerra J; Barbosa A; Pinto C; Arinto P; Resende A; Teixeira MR
Pharmacogenet Genomics; 2023 Oct; 33(8):165-171. PubMed ID: 37611150
[TBL] [Abstract][Full Text] [Related]
33. Upfront
Desilets A; McCarvill W; Aubin F; Bahig H; Ballivy O; Charpentier D; Filion É; Jamal R; Lambert L; Nguyen-Tan PF; Vadnais C; Weng X; Soulières D
Curr Oncol; 2022 Jan; 29(2):497-509. PubMed ID: 35200545
[No Abstract] [Full Text] [Related]
34. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
[TBL] [Abstract][Full Text] [Related]
35. Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles.
Granados J; Pasternak AL; Henry NL; Sahai V; Hertz DL
Clin Pharmacol Ther; 2024 Mar; 115(3):452-456. PubMed ID: 38060335
[TBL] [Abstract][Full Text] [Related]
36. Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk.
De Mattia E; Silvestri M; Polesel J; Ecca F; Mezzalira S; Scarabel L; Zhou Y; Roncato R; Lauschke VM; Calza S; Spina M; Puglisi F; Toffoli G; Cecchin E
Biomed Pharmacother; 2022 Oct; 154():113644. PubMed ID: 36063648
[TBL] [Abstract][Full Text] [Related]
37. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
[TBL] [Abstract][Full Text] [Related]
38. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
Medwid S; Wigle TJ; Kim RB
Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
[TBL] [Abstract][Full Text] [Related]
39. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
Jolivet C; Nassabein R; Soulières D; Weng X; Amireault C; Ayoub JP; Beauregard P; Blais N; Carrier C; Cloutier AS; Desnoyers A; Lemay AS; Lemay F; Loungnarath R; Jolivet J; Letendre F; Tehfé M; Vadnais C; Viens D; Aubin F
Oncologist; 2021 Apr; 26(4):e597-e602. PubMed ID: 33274825
[TBL] [Abstract][Full Text] [Related]
40. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Božina N; Bilić I; Ganoci L; Šimičević L; Pleština S; Lešnjaković L; Trkulja V
Br J Clin Pharmacol; 2022 May; 88(5):2190-2202. PubMed ID: 34780066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
